Literature DB >> 8235439

Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment.

J Kjeldsen1.   

Abstract

Treatment of acute attacks of ulcerative colitis in 89 patients with doses of prednisolone above or equal to 40 mg resulted in an overall remission in 67%. Remission rate and colectomy rate were 47% and 42%, respectively, when the disease was severe, 80% and 13% when moderate, and 84% and 3% when mild. The need for surgery was 28% in pancolitis, 11% in left-sided colitis, and 5% in proctitis. After subsequent treatment episodes colectomy was performed in 35% of patients with pancolitis, in 37% with left-sided colitis, and in 5% with proctitis. The median total duration of therapy in patients who went into clinical remission was 4 months, and the median dose just above 3 g prednisolone. Patients who stayed in remission during the follow-up received a significantly higher start dose and total dose of prednisolone in the treatment episode than patients who had a relapse. In 25 patients treatment with doses equal to or above 75 mg of prednisolone was continued beyond 10 days, and 11 patients experienced remission whereas 14 patients had surgery performed. Orally administered corticosteroids produce results comparable to those obtained after the previously suggested intravenous regimen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8235439     DOI: 10.3109/00365529309104016

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

Review 1.  Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy.

Authors:  W Connell; A Miller
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

2.  Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study.

Authors:  Bresci Giampaolo; Parisi Giuseppe; Bertoni Michele; Mazzoni Alessandro; Scatena Fabrizio; Capria Alfonso
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

Review 3.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

4.  Successful long-term use of infliximab in refractory pouchitis in an adolescent.

Authors:  Jessica Yeates; Mohsin Rashid
Journal:  Gastroenterol Res Pract       Date:  2011-01-12       Impact factor: 2.260

5.  Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.

Authors:  Adérson Omar Mourão Cintra Damião; Matheus Freitas Cardoso de Azevedo; Alexandre de Sousa Carlos; Marcela Yumi Wada; Taciana Valéria Marcolino Silva; Flávio de Castro Feitosa
Journal:  World J Gastroenterol       Date:  2019-03-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.